Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | PTGIR | P43119 | 1/20 | 0.50 |
| ▸ | COMT | P21964 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9829472 | 0.83 | ABCB1 (0.57) | CMA1SIGMAR1SMN1; SMN2GSK3AGSK3B | |
| SCHEMBL22469256 | 0.81 | PTGIR (0.60) | CMA1SIGMAR1SMN1; SMN2GSK3AGSK3B | |
| SCHEMBL12616547 | 0.80 | SIGMAR1 (0.61) | CMA1SIGMAR1SMN1; SMN2GSK3AGSK3B | |
| SCHEMBL3659094 | 0.80 | CMA1 (0.53) | CMA1SIGMAR1SMN1; SMN2GSK3AGSK3B | |
| SCHEMBL8107629 | 0.79 | SIGMAR1 (0.65) | CMA1SIGMAR1SMN1; SMN2GSK3AGSK3B | |
| SCHEMBL1586605 | 0.79 | SIGMAR1 (0.65) | CMA1SIGMAR1SMN1; SMN2GSK3AGSK3B | |
| SCHEMBL20804352 | 0.77 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL1043952 | 0.77 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL6450318 | 0.77 | SIGMAR1 (0.67) | CMA1SIGMAR1SMN1; SMN2GSK3AGSK3B | |
| SCHEMBL19285228 | 0.77 | SIGMAR1 (0.85) | SIGMAR1SMN1; SMN2ALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116969904-A | Compounds useful as autophagy modulators, methods of preparation and uses thereof | 微境生物医药科技(上海)有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3632903-B1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| CN-111148740-B | Compounds useful as autophagy modulators, methods of preparation and uses thereof | 微境生物医药科技(上海)有限公司 | 2023-08-25 | — | — | CN | disclosed |
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3632903-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20120238583-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-20 | — | — | US | disclosed |
| US-20120095017-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-20110245268-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20110118279-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-19 | — | — | US | disclosed |
| US-20100093752-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| US-7662823-B2 | Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090306095-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-7501420-B2 | Composition and antiviral of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-7354924-B2 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093752-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CMA1 49/4885SIGMAR1 2256/4885SMN1; SMN2 4747/4885 |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IMPDH2, IDO1 | CMA1 1343/4885SIGMAR1 969/4885SMN1; SMN2 4770/4885 |
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | ATG7, SQSTM1, BECN1 | CMA1 3263/4885SIGMAR1 3139/4885SMN1; SMN2 4684/4885 |
| US-20090306095-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CMA1 712/4885SIGMAR1 1181/4885SMN1; SMN2 4726/4885 |
| US-20110245268-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CMA1 49/4885SIGMAR1 2256/4885SMN1; SMN2 4747/4885 |
| US-20120238583-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CMA1 49/4885SIGMAR1 2256/4885SMN1; SMN2 4747/4885 |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | ATG7, SQSTM1, BECN1 | CMA1 3263/4885SIGMAR1 3139/4885SMN1; SMN2 4684/4885 |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CMA1 712/4885SIGMAR1 1181/4885SMN1; SMN2 4726/4885 |
| US-20120095017-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CMA1 49/4885SIGMAR1 2256/4885SMN1; SMN2 4747/4885 |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CMA1 112/4885SIGMAR1 2229/4885SMN1; SMN2 4851/4885 |
| US-20110118279-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CMA1 49/4885SIGMAR1 2256/4885SMN1; SMN2 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.